Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experienceLuca Stingeni, Donatella Schena, Maddalena Napolitano et al.|Journal of the European Academy of Dermatology and Venereology|2022Cited by 60
Long‐term drug survival of dupilumab and associated predictors in moderate‐to‐severe atopic dermatitis: A real‐world prospective cohort studyElena Pezzolo, Luigi Naldi, Mariateresa Rossi et al.|Journal of the European Academy of Dermatology and Venereology|2023Cited by 22
A 52‐week update of a multicentre Italian real‐world experience on effectiveness and safety of dupilumab in adolescents with moderate‐to‐severe atopic dermatitisLuca Stingeni, Leonardo Bianchi, Elettra Antonelli et al.|Journal of the European Academy of Dermatology and Venereology|2022Cited by 21
Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre studyFrancesca Barei, Silvia Mariel Ferrucci, Paolo Calzari et al.|Clinical and Experimental Dermatology|2025Cited by 5
Effectiveness of Tralokinumab Across Atopic Dermatitis PhenotypesFrancesca Barei, Silvia Mariel Ferrucci, Paolo Calzari et al.|Journal of Clinical Medicine|2025Cited by 5